Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-11
2010-06-15
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C544S262000, C548S360500, C548S373100
Reexamination Certificate
active
07737156
ABSTRACT:
The invention relates to the use of selective phosphodiesterase 9A (PDE9A) inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory.
REFERENCES:
patent: 3165520 (1965-01-01), Schmidt et al.
patent: 3732225 (1973-05-01), Breuer et al.
patent: 5002949 (1991-03-01), Peseckis et al.
patent: 5256668 (1993-10-01), Hsu et al.
patent: 5656629 (1997-08-01), Bacon et al.
patent: 5977118 (1999-11-01), Bacon et al.
patent: 6100037 (2000-08-01), Phillips et al.
patent: 2004/0266736 (2004-12-01), Wunder et al.
patent: 2006/0100222 (2006-05-01), Boss et al.
patent: 2006/0106035 (2006-05-01), Hendrix et al.
patent: 2006/0111372 (2006-05-01), Hendrix et al.
patent: 2007/0105876 (2007-05-01), Hendrix et al.
patent: 2007/0161662 (2007-07-01), Hendrix et al.
patent: 2 283 211 (1998-09-01), None
patent: 2 438 890 (2002-09-01), None
patent: 2 417 631 (2003-01-01), None
patent: 2 484 997 (2003-11-01), None
patent: 2 496 194 (2004-03-01), None
patent: 2 496 292 (2004-04-01), None
patent: 2 496 308 (2004-04-01), None
patent: 396 923 (1965-08-01), None
patent: 396 924 (1965-08-01), None
patent: 396 925 (1965-08-01), None
patent: 396 926 (1965-08-01), None
patent: 396 927 (1965-08-01), None
patent: 1 147 234 (1963-04-01), None
patent: 1 149 013 (1963-05-01), None
patent: 1 153 023 (1963-08-01), None
patent: 1 156 415 (1963-10-01), None
patent: 2 408 906 (1974-02-01), None
patent: 10156249 (2003-05-01), None
patent: 0 130 735 (1985-01-01), None
patent: 0 995 751 (2000-04-01), None
patent: 937726 (1963-09-01), None
patent: 973361 (1964-10-01), None
patent: 95/10506 (1995-04-01), None
patent: 98/10765 (1998-03-01), None
patent: 98/40384 (1998-09-01), None
patent: 99/41253 (1999-08-01), None
patent: 00/18758 (2000-04-01), None
patent: 02/06288 (2002-01-01), None
patent: 02/09713 (2002-02-01), None
patent: 02055082 (2002-07-01), None
patent: 02/068423 (2002-09-01), None
patent: 02/098864 (2002-12-01), None
patent: 03/041725 (2003-05-01), None
patent: 03037899 (2003-05-01), None
patent: 03/093269 (2003-11-01), None
patent: 2004/018474 (2004-03-01), None
patent: 2004/026286 (2004-04-01), None
patent: 2004/026876 (2004-04-01), None
Soderling SH, Bayuga SJ, Beavo JA. Indentificaiton and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases. J Biol Chem, Jun. 1998, 273(25), 15553-15558.
U.S. Appl. No. 10/524,956, filed Aug. 2003, Hendrix et al.
U.S. Appl. No. 10/556,437, filed Apr. 2004, Hendrix et al.
U.S. Appl. No. 10/556,224, filed Apr. 2004, Hendrix et al.
U.S. Appl. No. 10/525,115, filed Aug. 2003, Hendrix et al.
Ebert U and Kirch W, “Scopolamine model of dementia: electroencephalogram findings and cognitive performance,” European Journal of Clinical Investigation, Nov. 1998, 28(11), 944-949.
Prickaerts J, Steinbusch HW, Smits JF, and de Vente J, “Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast,” European Journal of Pharmacology, Oct. 1997, 337(2-3), 125-136.
Reid I, “Role of phosphodiesterase isozymes in the control of renin secretion: effects of selective enzyme inhibitors,” Current Pharmaceutical Design, Sep. 1999, 5(9), 725-735 (only abstract provided).
Weeber EJ, Levenson JM, and, Sweatt JD, “Molecular genetics of human cognition,” Molecular Interventions, Oct. 2002, 2(6), 376-391.
Byrn, et al., “Solid State Chemistry of Drugs,” 2nd ed., SSCI, Inc., Chapter 10, p. 232-247, 1999.
Vippagunta SR, Brittain HG, and Grant D J, “Crystalline solids,” Advanced Drug Delivery Reviews, May 2001,48(1), 3-26.
Database Medline, US National Library of Medicine (NLM), Bethesda, MD, US, 1997. Schousboe, et al., “Role of Ca+2 and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neurodegeneration: Clinical Perspectives.” Database Accession No. NLM9186041. Zusammenfassung & Clinical Neuroscience, New York, NY, 1997.
Fischer, et al., “Isolation and Characterization of PDE9A, a Novel Human cGMP-Specific Phosphodiesterase,”J. of Biological Chemistry, 273 (25): 15559-15564 (1998).
International Search Report for corresponding international application PCT/EP03/08880 mailed Apr. 16, 2004.
International Search Report for PCT/EP2004/006477 mailed Oct. 27, 2004.
International Search Report for PCT/03/08923 mailed Dec. 15, 2003.
International Search Report for PCT/EP03/08979 mailed Nov. 25, 2003.
International Search Report for PCT/EP2004/004412 mailed Jul. 14, 2004.
International Search Report for PCT/EP2004/004455 mailed Sep. 17, 2004.
International Search Report for PCT/EP2004/014872 mailed May 19, 2005.
Ji-Ye Wei, et al; Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System, Progress in Neurobiology (1998) vol. 56, pp. 37-64.
Douglas A. Fisher, et al; Isolation and Characterization of PDESA, A Novel Human cGMP-specific Phosphodiesterase; Journal of Biological Chemistry (1998) vol. 273, No. 25, pp. 15559-1 5564.
Michel Guipponi, et al; Identification and Characterization of a Novel Cydic Nudeotide Phosphodiesterase Gene (PDESA) That Maps to 21q22.3: Alternative Splicing of mRNA Transcripts, Genomic Structure and Sequence; Hum Genet (1998) vol. 103, pp. 386-392.
Svetlana G. Andreeva, et al; Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain, Journal of Neuroscience (2001) vol. 21, No. 22, pp. 9068-9076.
Timothy J. Martins, et al; Purification and Characterization of a Cydic GMP-stimulated Cyclic Nucledide Phosphodiesterase from Bovine Tissues, Journal of Biological Chemistry (1982) vol. 257, No. 4, pp. 1973-1979.
Sharron H. Francis, et al; Characterization of a Novel cGMP Binding Protein from Rat Lung, Journal of Biological Chemistry (1980) vol. 255, No. 2, pp. 620-626.
Peter G. Gillespie, et al; Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cydic GMP-Sepharose Chromatography; Journal of Biological Chemistry (1988) vol. 263. No. 17, pp. 8133-8141.
Lindsay Fawcett, et al; Molecular Cloning and Characterization of a Distinct Human Phosphodiesterase Gene Family: PDE11A; Proc. Natl. Acad.Sci.(2000) vol. 97, No. 7, pp. 3702-3707.
Seiko Murashima, et al; Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme; Biochemistry (1990) vol. 29, No. 22 pp. 5285-5292.
Scott H. Sonderling, et al; Regulation of CAMP and cGMP signaling: new phosphodiesterases and new functions; Current Opinion in Cell Biology (2000) vol. 12, pp. 174-179.
Akira Miyashita, et al; Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives. XVIII. Facile Preparation of 1H-Pyrazolo[3,4-d]Pyrimidin-4(5H)-Ones; Heterocycles (1990) vol. 31, No. 7, p. 1309-1314.
Kate Loughney, et al; Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated. 3′,5′-Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry (1996) vol. 271. No. 2, pp. 796-806.
Guy J. Rosman, et al; Isolation and Characterization of Human cDNAs encoding a cGMPstimulated 3′,5′-Cyclic Nucleotide Phosphodiesterase; Gene (1997) vol. 191, pp. 89-95.
Takashi Miki, et al; Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family; Genomics (1996) vol. 36, pp. 476-485.
Rena Obernolte, et al; The cDNA of a Human Lymphocyte cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family; Gene (1993) vol. 129, pp. 239-247.
Kate Loughney, et al; Isolation and Characterization of cDNAs encoding PDESA, a Human cGMP-Binding, cGMP-Speafic Y.9-Cydic Nudeotide Phosphodiesterase; Gene (1998) vol. 216, pp. 139-147.
J. M. Hetman, et al; Cloning and Characterization of PDE7B, a CAMP-specific Phosphodiesterase, Proc. Natl. Acad. Sci. (2000) vol. 97, No. 1, pp. 472-476.
Douglas A. Fisher, et al; Isolation and Characterization of PDEM, a Novel Human CAMP-Specific Phosphodiesterase; Biochemic
Böβ Frank-Gerhard
Erb Christina
Hendrix Martin
van Kampen Marja
Wunder Frank
Boehringer Ingelheim International GmbH
Devlin Mary-Ellen M.
Fetterolf Brandon J
Lebel Edouard G.
Morris Michael P.
LandOfFree
Selective phosphodiesterase 9A inhibitors as medicaments for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective phosphodiesterase 9A inhibitors as medicaments for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective phosphodiesterase 9A inhibitors as medicaments for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199817